Articles related to CLINICAL TRIALS

At ECTRIMS-ACTRIMS 2023, pivotal studies like the OLIKOS and MIRANTIBUS trials have highlighted the evolving dynamics in MS treatment, particularly emphasizing the shift towards more patient-centric and effective therapeutic approaches.

In a novel approach to combat metastatic castration-resistant prostate cancer, ODM-208, targeting cytochrome P450 11A1, has shown promising results in reducing prostate-specific antigens and testosterone levels, offering new hope in a challenging therapeutic area.

Highlighting a paradigm shift in breast cancer treatment, the NRG Oncology/NSABP B-51/RTOG 1304 study demonstrates that certain patients with node-negative breast cancer post-neoadjuvant chemotherapy may safely omit adjuvant regional nodal irradiation, challenging conventional treatment approaches and potentially improving patient quality of life.

An in-depth look at the FDA’s clinical hold on Iovance’s lung cancer cell therapy trial reveals crucial insights into the safety and progression of innovative cancer treatments.

In a significant shift, a new phase 3 trial suggests reconsidering adjuvant radiotherapy after radical prostatectomy, as many patients may not require it long-term, potentially reducing morbidity risks.

The significant reduction in the incidence of death from cardiovascular causes, nonfatal MI, or nonfatal stroke highlights the need for further research into the benefits of semaglutide in this patient population.